emsam (deprenyl patch): how a promising antidepressant was underutilized [corrigendum]
Clicks: 67
ID: 210583
2014
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
19.8
/100
66 views
12 readers
Trending
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Asnis GM, Henderson MA. Neuropsychiatr Dis Treat. 2014;10:1911–1923.On page 1921 “[…] Dye and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb” should be “Dey and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb”.On page 1921 “Both Dye and Mylan’s recent attempts at reanalysis […]” should be “Both Dey and Mylan’s recent attempts at reanalysis […]”.On page 1921 “With over 14 years left in the patent of EMSAM, [...]” should be “with 4 years left in the patent of EMSAM, [...]”. The authors apologize for these errors.Read the original article
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (111 words).
Try re-searching for a better abstract.
| Reference Key |
gm2014neuropsychiatricemsam
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Asnis GM;Henderson MA |
| Journal | journal of crystal growth |
| Year | 2014 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.